age related macular degeneration
More than one million Americans aged 40 and over are affected by geographic atrophy (otherwise known as advanced dry age-related macular degeneration), which currently has no available therapy that...
The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
age-related macular degeneration
Geographic atrophy typically affects people over the age of 50 and is one of the main causes of vision loss in the United States.
Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.